For patients receiving less intensive treatments, an important factor affecting the prognosis and the response to VEN-azacitidine (AZA) in NPM1-mutated AML is the co-presence of activating signaling mutations (FLT3-ITD, KRAS, NRAS). This evidence concerns the gene FLT3 and acute myeloid leukemia.